TSBX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 32.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Turnstone Biologics Share Price & Price History
Current Price: $0.36
Price Change: +0.30 (1.20%)
As of 08/11/2025 01:00 AM ET
Turnstone Biologics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/25/2023 | Versant Ventures V, Llc | Major Shareholder | Buy | 225,000 | $12.00 | $2,700,000.00 | 2,726,322 |  |
| 7/20/2023 | Rishi Gupta | Director | Buy | 416,666 | $12.00 | $4,999,992.00 | 3,099,265 | |
Turnstone Biologics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 7/18/2025 | Deltec Asset Management LLC | 106,057 | $38K | 0.0% | N/A | 0.458% |  |
| 5/7/2025 | BML Capital Management LLC | 1,103,386 | $0.45M | 0.3% | N/A | 4.769% | |
| 2/17/2025 | Millennium Management LLC | 73,744 | $37K | 0.0% | -28.4% | 0.319% | |
| 2/12/2025 | Takeda Pharmaceutical Co. Ltd. | 895,824 | $0.45M | 1.7% | N/A | 3.873% | |
| 11/15/2024 | Point72 Asset Management L.P. | 932,226 | $0.52M | 0.0% | -16.7% | 4.030% | |
| 11/13/2024 | FMR LLC | 1,172,987 | $0.65M | 0.0% | +3.3% | 5.071% | |
| 8/19/2024 | Point72 Asset Management L.P. | 1,118,588 | $2.93M | 0.0% | -5.5% | 4.837% | |
| 8/13/2024 | Sei Investments Co. | 11,882 | $31K | 0.0% | N/A | 0.051% | |
| 5/17/2024 | Zimmer Partners LP | 179,026 | $0.47M | 0.0% | +271.4% | 0.774% | |
| 4/17/2024 | Kathleen S. Wright Associates Inc. | 42,553 | $0.11M | 0.1% | N/A | 0.184% | |
| 2/15/2024 | PFM Health Sciences LP | 633,313 | $1.61M | 0.1% | -58.5% | 2.742% | |
| 2/15/2024 | Caas Capital Management LP | 45,831 | $0.12M | 0.0% | -40.1% | 0.198% | |
| 12/6/2023 | Citigroup Inc. | 7,524 | $30K | 0.0% | N/A | 0.033% | |
| 11/15/2023 | Sectoral Asset Management Inc. | 517,648 | $2.04M | 0.4% | N/A | 2.266% | |
| 11/14/2023 | Eventide Asset Management LLC | 708,317 | $2.79M | 0.1% | N/A | 3.101% | |
| 11/13/2023 | FMR LLC | 2,830,284 | $11.15M | 0.0% | N/A | 12.392% | |
| 11/7/2023 | New York State Common Retirement Fund | 18,867 | $74K | 0.0% | N/A | 0.083% | |
Data available starting January 2016
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Read More on Turnstone Biologics
Volume
N/A
Average Volume
142,319 shs
Market Capitalization
$8.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.36
